The US FDA’s emergency use authorization of a booster dose for Pfizer Inc./BioNTech SE’s COVID vaccine limits the third dose to certain populations 18 and up – an age restriction that was not part of the advisory committee vote last week, but is consistent with concerns about myocarditis in younger recipients.
The EUA is for a single booster dose, at least six months after completion of the primary series in:







